MartinLutherKing
16 minutes ago
The expanding clinical application as well as together with indication of CRISPR/Cas9, mounting preclinical and clinical trials, rise in technological advancement, presences of key players like Intellia Therapeutics, CRISPR Therapeutics, Editas Medicine, TransCode Therapeutics and many more, combina
Slojab
17 minutes ago
As of November 18, 2024, the issuer had 2,369,037,729 shares of its common stock issued and outstanding
Outstanding Shares 5,469,037,729 01/02/2025
Restricted 3,457,147,781 01/02/2025
Unrestricted 2,011,889,948 01/02/2025
On December 30, 2024, Two Hands Co